Clinical Trial Update: Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat [Phase 2]

View source ↗

Summary

Phase 2 trial investigating plasmid electroporation with pembrolizumab and epacadostat in metastatic/recurrent unresectable head and neck squamous cell carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Epacadostat (epacadostat)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Chase Heaton, MD | Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2023-05-09